Osteoclast inhibitors for knee conditions
View Patent ↗Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
1. A method of treating knee pain comprising:
a. selecting a patient having knee pain, and:
i. OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing, or
ii. pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS; and
b. administering an inhibitor of osteoclast activity to the patient
wherein the inhibitor of osteoclast activity is ibandronic acid or risedronic acid.
2. The method of claim 1 , comprising selecting a patient having OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing.
3. The method of claim 1 , comprising selecting a patient having pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS.
4. The method of claim 2 , comprising selecting a patient having pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS.
5. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice.
6. The method of claim 5 , wherein the inhibitor of osteoclast activity is administered about every three months, or more frequently.
7. The method of claim 1 , wherein the patient experiences pain relief within about three months after the inhibitor of osteoclast activity is administered to the patient.
8. The method of claim 7 , wherein the patient experiences pain relief at least 24 hours after the inhibitor of osteoclast activity is administered to the patient.
9. The method of claim 1 , wherein the inhibitor of osteoclast activity is ibandronic acid.
10. The method of claim 1 , wherein the inhibitor of osteoclast activity is risedronic acid.
11. The method of claim 1 , wherein the patient experiences a reduction in pain intensity—when using a 100 mm visual analog scale—of at least about 5.
12. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice over a period of at least four weeks.
13. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered once weekly for a period of six weeks.
14. The method of claim 13 , wherein the weekly dose of the inhibitor of osteoclast activity is between about 25 mg and about 75 mg.
15. The method of claim 1 , wherein patient is about 10 years to about 90 years old.
16. The method of claim 9 , wherein patient is about 10 years to about 90 years old.
17. The method of claim 10 , wherein patient is about 10 years to about 90 years old.
18. The method of claim 1 , wherein the patient has suffered from knee pain for at least two months.
19. The method of claim 9 , wherein the patient has suffered from knee pain for at least two months.
20. The method of claim 10 , wherein the patient has suffered from knee pain for at least two months.
21. The method of claim 1 , wherein the patient has reduced knee pain that lasts for at least three hours after administration.
22. The method of claim 1 , wherein the method results in the patient reducing use of non-steroidal anti-inflammatory drugs (NSAIDS), opioids, or other pain medication.
23. The method of claim 22 , wherein the reduced use of NSAIDs, opioids, or other pain medication is by at least 5%.
24. The method of claim 22 , wherein the reduced use of NSAIDs, opioids, or other pain medication is observed at about one week after administration.
25. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered orally, rectally, or parenterally.
26. The method of claim 1 , wherein the inhibitor of osteoclast activity is orally administered in the form of a tablet, a pill, a capsule, a buccal tablet, a coated tablet, a troche, a capsule, an elixir, a dispersion, a suspension, a solution, a syrup, a wafer, or a patch.
27. The method of claim 1 , wherein the inhibitor of osteoclast activity is in a salt form.
28. The method of claim 25 , wherein each oral dosage form comprises about 0.005 mg to about 2000 mg of the inhibitor of osteoclast activity.
29. The method of claim 28 , wherein about 0.005 mg to about 20 mg of the inhibitor of osteoclast activity is orally administered daily.
30. The method of claim 25 , wherein about 5000 mg or less of the inhibitor of osteoclast activity is administered over a period of a month.